• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • GLP-1 Receptor Agonist
    2 Drugs classified under this drug class

    All the Drug Class Drugs

    Trulicity 0.75 mg, 1.5 mg
    Eli Lilly
    partial basket chart
    Trulicity 0.75 mg, 1.5 mg

    GLP-1 Receptor Agonist. Dulaglutide 0.75 mg, 1.5 mg.
    PRE-FILL. SYR.: 4× 0.5 ml (sol.). Monother.: 0.75 mg once wkly. Add-on ther.: 1.5 mg once wkly. For potent. vulnerable populat., such as patients ≥ 75 yrs., 0.75 mg once wkly. can be consid. as a init. dose. When added to exist. metformin and/or pioglitazone ther., the current dose of metformin and/or pioglitazone can be cont.. When it is added to exist. ther. of a sulphonylurea/ prandial insulin, a reduct. in the dose of sulphonylurea or
    insulin may be consid. to reduce the risk of hypoglycaemia. See lit.
    Indicated in adults with type 2 diab. mell. to improve glycaemic control as: Monother.: When diet& exercise alone do not provide adeq. glycaem. control in pts. for whom the use of metformin is consid.
    inappropr. due to intoler. or contraind. Add-on therapy: In comb. with other glucose-low. med. products includ. insulin, when these, together with diet and exercise, do not provide adequate
    glycaemic control.
    C/I: Hypersens.

    Novo Nordisk
    partial basket chart

    GLP-1 Receptor Agonist. Liraglutide 6 mg/ml.
    PRE-FILLED PEN (sol. for inject): 30 doses
    of 0.6 mg, 15 doses of 1.2 mg, or 10
    doses of 1.8 mg. Initial: 0.6 mg S.C. 1 x dly for 1 wk, then incr. to 1.2 mg S.C. 1
    x dly for at least 1 wk. Max dose 1.8 mg
    S.C. 1 x dly.
    Tmt. adults with type 2 diabetes mellitus
    to achieve glycem. control. In comb.
    with: Metformin or sulphonylurea, in pts
    with insuff. glycem. control despite max.
    tolerat. dose of monother. with
    metformin or sulphonylurea; In
    combinat. with metformin and a
    sulphonylurea/thiazolidinedione in pts
    with insuff. glycem. control despite dual
    C/I: Hypersens.